Matthew Buten
CIK 1898799 · Chief Financial Officer · last filed 2026-03-03
Matthew Buten is a Chief Financial Officer who has filed 12 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for BHVN, was dated Mar 3, 2026. Across all open-market trades the lifetime net is +$2.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.24M
2
12
$2.00M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BHVN | Chief Financial Officer | 198,246 | $11.28 | $2.24M | $2.00M | 10 | 2026-03-03 |
| Biohaven Pharmaceutical Holding Co Ltd. (BHVNw) Delisted | Chief Financial Officer | 0 | — | — | $0 | 1 | 2022-10-03 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-03 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2026-01-07 | BHVN | Mixed | +1,656 | -$25.8K | EDGAR |
| 2025-01-07 | BHVN | Mixed | +1,689 | -$99.0K | EDGAR |
| 2024-01-04 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2023-11-06 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2023-10-06 | BHVN | Buy (P) | +22,727 | $500.0K | EDGAR |
| 2022-10-26 | BHVN | Buy (P) | +142,857 | $1.50M | EDGAR |
| 2022-10-05 | — | Mixed | +23,796 | -$5 | |
| 2022-10-03 | Biohaven Pharmaceutical Holding Co Ltd. (BHVNw) Delisted | Disp (D) | −6,177 | -$917.3K | EDGAR |
| 2022-01-07 | BHVN | Grant (A) | — | $0 | EDGAR |